Bio View (Israel) Investor Sentiment

BIOV Stock  ILS 25.30  0.90  3.44%   
About 62% of Bio View's investor base is looking to short. The analysis of current outlook of investing in Bio View suggests that many traders are alarmed regarding Bio View's prospects. The current market sentiment, together with Bio View's historical and current headlines, can help investors time the market. In addition, many technical investors use Bio View stock news signals to limit their universe of possible portfolio assets.
  
over six months ago at news.google.com         
Should Biotechnology Stock KALA BIO Inc Be in Your Portfolio Wednesday - InvestorsObserver
Google News at Macroaxis
over six months ago at news.google.com         
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635 - Business Wire
Google News at Macroaxis
over six months ago at news.google.com         
EyePoint sees stock surge on AMD drug trial data - BioPharma Dive
Google News at Macroaxis
over six months ago at news.google.com         
Shareholders Will Probably Not Have Any Issues With Bio-View Ltds CEO Compensation - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
BioHarvest Sciences to Host Virtual Shareholder Update December ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Will Annovis Bio Inc Outperform the Rest of the Stocks in the Healthcare Sector - InvestorsObserver
Google News at Macroaxis
over a year ago at news.google.com         
BioHarvest Sciences Reports Q3 2023 Revenue Demonstrating ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
INVO Bioscience Regains Compliance with Nasdaq Minimum ... - BioSpace
Google News at Macroaxis
over a year ago at news.google.com         
BIO-TECHNE TO PRESENT AT THE 6TH ANNUAL EVERCORE ISI ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Benavidez Dismantles Andrade Will Canelo Be Next Boxing ... - The Sweet Science
Google News at Macroaxis
over a year ago at news.google.com         
Should You Add 2Seventy Bio Inc Stock to Your Portfolio Friday - InvestorsObserver
Google News at Macroaxis
over a year ago at news.google.com         
Is Bio-Rad Laboratories, Inc. Class A Common Stock a Loser in the Healthcare Sector - InvestorsObser...
Google News at Macroaxis
over a year ago at news.google.com         
Skip Therapeutics and Sheba Medical Center to Collaborate for the ... - InvestorsObserver
Google News at Macroaxis
over a year ago at news.google.com         
COO CFO of Gossamer Bio Picks Up 76 percent More Stock - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
Bluebird Bio To Rally Around 267 Here Are 10 Top Analyst Forecasts For Wednesday - bluebird bio NASD...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Bio View that are available to investors today. That information is available publicly through Bio media outlets and privately through word of mouth or via Bio internal channels. However, regardless of the origin, that massive amount of Bio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Bio View news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Bio View relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Bio View's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Bio View alpha.

Bio View Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Bio Stock analysis

When running Bio View's price analysis, check to measure Bio View's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio View is operating at the current time. Most of Bio View's value examination focuses on studying past and present price action to predict the probability of Bio View's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio View's price. Additionally, you may evaluate how the addition of Bio View to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance